Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: Forums: Virtual Conferences
1998 Society of Neuroscience Meeting


back to News

Complement cascade activation by neurofibrillary tangles

by Aileen Anderson

10 November 1998. The complement cascade is a complex inflammatory process that can mediate diverse functions, from targeting cells and cellular components for phagocytosis to membrane attack complex-mediated cell death. In this context, there are twenty or more individual proteins that participate in the complement cascade. Immunoreactivity for a wide variety of complement proteins, e.g. C1q and the terminal membrane attack complex (MAC or C5b-9), has been reported in association with both ß-amyloid plaques and neurofibrillary tangles (NFT) in AD brain. Previous work by several laboratories including that of Joseph Rogers and Andrea Tenner, has demonstrated that ß-amyloid 1-42 can activate complement and bind complement proteins including the C1q A chain. In a newer study, Rogers, et al., report that a purified fraction of isolated NFTs can also activate a complement response (abstract 502.10). Recombinant tau also activated terminal complement in a dose-dependent manner nearly as efficiently as synthetic Aß 1-42. Further, a fraction of isolated tau that formed fibrils, as compared to soluble recombinant tau, activated complement even more strongly. These data may suggest that both ß-amyloid plaques and NTFs could serve as chronic mediators of an inflammatory response in the AD brain.




Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2012 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad